Photo by wulcan from unsplash
Immunogenicity causing development of anti‐drug antibodies (ADAs) are major challenges in the treatment of haemophilia, as well as other diseases where proteins are used for treatment. Furthermore, it is a… Click to show full abstract
Immunogenicity causing development of anti‐drug antibodies (ADAs) are major challenges in the treatment of haemophilia, as well as other diseases where proteins are used for treatment. Furthermore, it is a complication for preclinical testing of such therapies in animal models.
Keywords:
ctla4 prevents;
development;
neutralizing antibody;
treatment;
development neutralizing;
prevents development
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!